Jump to content

Pfizer to help patients pay for new med


KatieB

Recommended Posts

Pfizer to help patients pay for pricey new cancer med - FiercePharma: bit.ly/reOSmb

Pfizer's ($PFE) Lipitor gap is beginning to fill in. The company won FDA approval for its targeted lung cancer drug Xalkori, which some analysts expect to add a very healthy $2.5 billion in peak sales to the top line. That's partly because the drug carries a gold-plated price tag: $9,600 per month, or $115,000 for a year's worth of treatment.

Pfizer has plans for cutting patients' share of that cost significantly. The company is offering copay assistance of up to $24,000 per year with a program that would have privately insured patients pay only $100 per prescription. If a patient had a 20% copay, that would cover a year's worth of treatment. The company also says it will help patients who are uninsured--or insured by Medicaid or Medicare--figure out how to cover Xalkori's costs. But as Forbes points out, Pfizer's assistance programs don't help payers cover their costs.

Sign up for our FREE newsletter for more news like this sent to your inbox!

Whatever the price tag, Xalkori represents a significant milestone for cancer treatment--it's the first new lung cancer med in 6 years, and the first for this subgroup of patients with the ALK genetic mutation. It's also a significant milestone for Pfizer, which has struggled in recent years to bring new drugs to market.

It's also a milestone for companion diagnostics; along with the Xalkori approval came a nod for Abbott Laboratories' ($ABT) test to identify patients with the ALK mutation. "Xalkori represents a new chapter in personalized therapy for lung cancer, enabling physicians to provide the right treatment for the right patient," Pfizer's Mace Rothenberg said in a statement. Abbott's Stafford O'Kelly echoed that in his own statement: "The Abbott-Pfizer collaboration marks a breakthrough in the advancement of personalized medicine--and companion diagnostics specifically--that will help a subset of lung-cancer patients get treatment tailored to their unique genetic profile."

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.